Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Credit Agricole Q1 earnings grow, corporate and investment units outperform rivals

(Sharecast News) - French banking group Credit Agricole said on Friday that first-quarter earnings had grown as its corporate and investment banking units outperformed rivals. Net profits rose to €1.9bn in the three months ended 31 March, above the €1.48bn expected by analysts, while sales rose 11% to €6.81bn, topping expectations for a reading of €6.47bn. Credit Agricole also noted that it had put aside €400.0m for bad loans in Q1, €105.0m less than expected.

However, despite reporting an overall rise in revenues, Credit Agricole said retail sales in France grew just 1.8% and said its net interest margin remained stable.

The French lender highlighted that revenues in its corporate and investment banking businesses, which make up quarter of all revenues, rose 4% year-on-year, while revenue from trading in fixed income, currencies and commodities shrank 3%, outperforming rival BNP Paribas.

As of 1010 BST, Credit Agricole shares were up 3.63% at €15.14 each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.